Literature DB >> 21125316

Knockdown of ribonuclease inhibitor expression with siRNA in non-invasive bladder cancer cell line BIU-87 promotes growth and metastasis potentials.

Junxia Chen1, Xi Ou-Yang, Juan Gao, Jun Zhu, Xiaoyan He, Jiang Rong.   

Abstract

Human ribonuclease inhibitor (RI) is a cytoplasmic acidic protein. RI is constructed almost entirely of leucine-rich repeats, which might be involved in some unknown biological functions like other structurally similar proteins besides inhibiting RNase A and angiogenin activities. Our previous experiments demonstrated that up-regulating RI might effectively inhibit some tumor growth and metastasis. However, the down-regulating RI influence on the tumor does not have any report until now, the mechanisms underlying antitumor of RI have not been fully understood. In this study, the efficient RNA interferences of RI were constructed using a plasmid vector and identified with RT-PCR, Western blot and Immunocytochemistry, then were transfected into non-invasive bladder cancer BIU-87 cells. We demonstrated that knockdown RI expression in BIU-87 cells could obviously change the cell morphology, rearrange the microfilaments and extend the lamellipodia, as well as enhance proliferation, increase migration, invasion and matrix metalloprotease level, and also reduce adhesion in vitro. BALB/C nude mice that were injected with the BIU-87 cells transfected RI siRNA showed a significant facilitation of the tumor with heavier tumor weight, higher density of microvessels, lower nm23-H1 and E-Cadherin expressions than those in the control group. Taken together, these experiments suggest that knockdown of RI could promote growth and metastasis potentials of BIU-87 cells. Our present findings reveal the novel mechanism that anti-tumor effect of RI is also involved in suppressing growth and metastasis, besides antiangiogenesis. The results show that RI may be a therapeutic target protein for bladder cancer and may be of biological importance.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21125316     DOI: 10.1007/s11010-010-0663-7

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  26 in total

1.  Cytoplasmic ribonuclease inhibitor.

Authors:  R Shapiro
Journal:  Methods Enzymol       Date:  2001       Impact factor: 1.600

2.  Antitumor effects of human ribonuclease inhibitor gene transfected on B16 melanoma cells.

Authors:  Jun-Xia Chen; Ying Gao; Ji-Wei Liu; Yu-Xiang Tian; Jing Zhao; Xiu-Yun Cui
Journal:  Int J Biochem Cell Biol       Date:  2005-01-13       Impact factor: 5.085

3.  Implication of metastasis suppressor NM23-H1 in maintaining adherens junctions and limiting the invasive potential of human cancer cells.

Authors:  Mathieu Boissan; Olivier De Wever; Floria Lizarraga; Dominique Wendum; Renaud Poincloux; Nicolas Chignard; Christèle Desbois-Mouthon; Sylvie Dufour; Béatrice Nawrocki-Raby; Philippe Birembaut; Marc Bracke; Philippe Chavrier; Christian Gespach; Marie-Lise Lacombe
Journal:  Cancer Res       Date:  2010-09-14       Impact factor: 12.701

4.  Characterization of 3 oral squamous cell carcinoma cell lines with different invasion and/or metastatic potentials.

Authors:  N Fazil Erdem; Eric R Carlson; David A Gerard; Albert T Ichiki
Journal:  J Oral Maxillofac Surg       Date:  2007-09       Impact factor: 1.895

5.  MicroRNA-21 targets tumor suppressor genes in invasion and metastasis.

Authors:  Shuomin Zhu; Hailong Wu; Fangting Wu; Daotai Nie; Shijie Sheng; Yin-Yuan Mo
Journal:  Cell Res       Date:  2008-03       Impact factor: 25.617

6.  Binding of placental ribonuclease inhibitor to the active site of angiogenin.

Authors:  F S Lee; B L Vallee
Journal:  Biochemistry       Date:  1989-04-18       Impact factor: 3.162

7.  [Analysis of gene expression of ribonuclease inhibitor in human breast cancer tissue].

Authors:  Yu-Xiang Tian; Dong-Mei Wang; Xiu-Yun Cui
Journal:  Ai Zheng       Date:  2004-03

8.  Effect of treatment on mononuclear cell migration in cervical cancer patients.

Authors:  Cristiana Bernadelli Garcia; Paulo Cesar Júnior Fernandes; Douglas Côbo Micheli; Ana Helena Macedo Pereira; Eddie Fernando Candido Murta; Beatriz Martins Tavares-Murta
Journal:  Tumori       Date:  2008 Sep-Oct

9.  Downregulation of CD147 expression alters cytoskeleton architecture and inhibits gelatinase production and SAPK pathway in human hepatocellular carcinoma cells.

Authors:  Ai-Rong Qian; Wei Zhang; Jian-Ping Cao; Peng-Fei Yang; Xiang Gao; Zhe Wang; Hui-Yun Xu; Yuan-Yuan Weng; Peng Shang
Journal:  J Exp Clin Cancer Res       Date:  2008-10-11

10.  Stress fibers are generated by two distinct actin assembly mechanisms in motile cells.

Authors:  Pirta Hotulainen; Pekka Lappalainen
Journal:  J Cell Biol       Date:  2006-05-01       Impact factor: 10.539

View more
  8 in total

1.  Overexpression of ribonuclease inhibitor defines good prognosis and suppresses proliferation and metastasis in human colorectal cancer cells via PI3K/AKT pathway.

Authors:  Y Tang; P Liu; Y Tian; Y Xu; F Ren; X Cui; J Fan
Journal:  Clin Transl Oncol       Date:  2014-09-26       Impact factor: 3.405

2.  Silencing of HMGA1 expression by RNA interference suppresses growth of osteogenic sarcoma.

Authors:  Shaohui Yuan; Qi Pan; Chunjiang Fu; Zhenggang Bi
Journal:  Mol Cell Biochem       Date:  2011-05-15       Impact factor: 3.396

3.  Knockout of the Ribonuclease Inhibitor Gene Leaves Human Cells Vulnerable to Secretory Ribonucleases.

Authors:  Sydney P Thomas; Eunji Kim; Jin-Soo Kim; Ronald T Raines
Journal:  Biochemistry       Date:  2016-11-08       Impact factor: 3.162

4.  B-Myb regulates snail expression to promote epithelial-to-mesenchymal transition and invasion of breast cancer cell.

Authors:  Deyou Tao; Yihong Pan; Guobin Jiang; Hongsheng Lu; Song Zheng; Hui Lin; Feilin Cao
Journal:  Med Oncol       Date:  2014-12-11       Impact factor: 3.064

5.  Regulation of IRE1 RNase activity by the Ribonuclease inhibitor 1 (RNH1).

Authors:  Quentin Tavernier; Evangeline Bennana; Virginie Poindessous; Celine Schaeffer; Luca Rampoldi; Nicolas Pietrancosta; Nicolas Pallet
Journal:  Cell Cycle       Date:  2018-09-05       Impact factor: 4.534

6.  Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon?

Authors:  Olga Golubnitschaja; Kristina Yeghiazaryan; Vincenzo Costigliola; Daniela Trog; Michael Braun; Manuel Debald; Walther Kuhn; Hans H Schild
Journal:  EPMA J       Date:  2013-02-19       Impact factor: 6.543

7.  Plasma autoantibodies against heat shock protein 70, enolase 1 and ribonuclease/angiogenin inhibitor 1 as potential biomarkers for cholangiocarcinoma.

Authors:  Rucksak Rucksaken; Chawalit Pairojkul; Porntip Pinlaor; Narong Khuntikeo; Sittiruk Roytrakul; Carlo Selmi; Somchai Pinlaor
Journal:  PLoS One       Date:  2014-07-24       Impact factor: 3.240

8.  A new non-muscle-invasive bladder tumor-homing peptide identified by phage display in vivo.

Authors:  Xiaofeng Yang; Fan Zhang; Junqian Luo; Jianzhi Pang; Sanhua Yan; Fang Luo; Jiehao Liu; Wei Wang; Yongping Cui; Xixi Su
Journal:  Oncol Rep       Date:  2016-05-23       Impact factor: 3.906

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.